美国华盛顿大学医学院David M. Holtzman团队针对阿尔茨海默病（AD）进行了病理学和治疗策略相关的综述。2019年9月26日，《细胞》在线发表了这一论文。

研究人员介绍，AD是一种具有复杂病理生物学特性的异质性疾病。细胞外β-淀粉样蛋白沉积为神经炎斑块和高磷酸化tau的细胞内积累为神经原纤维缠结的存在，仍然是AD诊断的主要神经病理学标准。但是，最近的一些基本发现凸显了其他关键细胞和分子过程的重要病理作用。尽管如此，目前尚无改善疾病的治疗方法，而且许多3期临床试验均未能证明其益处。

研究人员回顾了人们对AD病理生物学理解的最新进展，并讨论了当前的治疗策略，重点介绍了最新的临床试验和开发未来疾病修饰疗法的机会。

附：英文原文

Title: Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Author: Justin M. Long, David M. Holtzman

Issue&Volume: 26 September 2019

Abstract: 

Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathologic criteria for AD diagnosis. However, a number of recent fundamental discoveries highlight important pathological roles for other critical cellular and molecular processes. Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clinical trials have failed to demonstrate benefits. Here, we review recent advances in our understanding of AD pathobiology and discuss current treatment strategies, highlighting recent clinical trials and opportunities for developing future disease-modifying therapies.

DOI: 10.1016/j.cell.2019.09.001

Source: https://www.cell.com/cell/fulltext/S0092-8674(19)31007-4